1
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
et al: SEER cancer statistics review, 1975–2010Natl Cancer Inst.
Bethesda, MD, USA: 2013
|
2
|
Simard EP, Ward EM, Siegel R and Jemal A:
Cancers with increasing incidence trends in the United States: 1999
through 2008. CA Cancer J Clin. 62:118–128. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Siegel R, Ma JM, Zou ZH and Jemal A:
Cancer Statistics, 2014. CA Cancer J Clin. 64:9–29. 2014.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Lin S, Hoffmann K and Schemmer P:
Treatment of hepatocellular carcinoma: A systematic review. Liver
Cancer. 1:144–158. 2012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Lu SC: Where are we in the chemoprevention
of hepatocellar carcinoma? Hepatology. 51:734–736. 2010.PubMed/NCBI
|
7
|
Villanueva A and Llovet JM: Targeted
therapies for hepatocellular carcinoma. Gastroenterol.
140:1410–1426. 2011. View Article : Google Scholar
|
8
|
Darvesh AS, Aggarwal BB and Bishayee A:
Curcumin and liver cancer: A review. Curr Pharm Biotechnol.
13:218–228. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Nurse P: Ordering S phase and M phase in
the cell cycle. Cell. 79:547–550. 1994. View Article : Google Scholar : PubMed/NCBI
|
11
|
Morgan DO: Principles of CDK regulation.
Nature. 374:131–134. 1995. View
Article : Google Scholar : PubMed/NCBI
|
12
|
Haraken S, Abu-EI-Ardat K, Diab-Assaf M,
Niedzwiecki A, EI-Sabban M and Rath M: Epigallocatechin-3-gallate
induces apoptosis and cell cycle arrest in HTLV-1-positive and
-negative leukemia cells. Med Oncol. 25:30–39. 2008. View Article : Google Scholar : PubMed/NCBI
|
13
|
Purohit A, Hejaz HA, Walden L,
MacCarthy-Morrogh L, Packham G, Potter BVL and Reed MJ: The effect
of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer
cells and induced mammary tumors. Int J Cancer. 85:584–589. 2000.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Kessel D and Luo Y: Cells in
cryptophycin-induced cell-cyclearrest are susceptible to apoptosis.
Cancer Lett. 151:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
15
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Cory S and Adams JM: The Bcl-2 family:
Regulators of the cellular life-of-death switch. Nat Rev Cancer.
2:647–656. 2002. View
Article : Google Scholar : PubMed/NCBI
|
17
|
Peng J, Ding J, Tan C, Baggenstoss B,
Zhang Z, Lapolla SM and Lin J: Oligomerization of membrane-bound
Bcl-2 is involved in its pore formation induced by tBid. Apoptosis.
14:1145–1153. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Peng J, Tan C, Roberts GJ, Nikolaeva O,
Zhang Z, Lapolla SM, Primorac S, Andrews DW and Lin J: tBID elicits
a conformational alteration in membrane-bound Bcl-2 such that it
inhibits Bax pore formation. J Biol Chem. 281:35802–35811. 2006.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Valencia-Sachez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
20
|
Bagga S and Pasquinelli AE: Identification
and analysis of microRNAs. Genet Eng (NY). 27:1–20. 2006.
View Article : Google Scholar
|
21
|
Bar N and Dikstein R: miR-22 forms a
regulatory loop in PTEN/AKT pathway and modulates signaling
kinetics. PLoS One. 5:e108592010. View Article : Google Scholar : PubMed/NCBI
|
22
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Bartel DP: MicroRNA: Target recognition
and regulatory function. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
24
|
Leskelä S, Leandro-García LJ, Mendiola M,
Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo
A, de Santiago J, Robledo M, et al: The mir-200 family controls
beta-tubulin III expression and is associated with paclitaxel-based
treatment response and progression-free survival in ovarian cancer
patients. Endocr Relat Cancer. 18:85–95. 2011. View Article : Google Scholar : PubMed/NCBI
|
25
|
Uhlmann S, Zhang J, Schwäger A,
Mannsperger H, Riazalhosseini Y, Burmester S, Ward A, Korf U,
Wiemann S and Sahin Ö: miR-200bc/429 cluster targets PLCgamma1 and
differentially regulates proliferation and EGF-driven invasion than
miR-200a/141 in breast cancer. Oncogene. 29:4297–4306. 2010.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Li H, Tang J, Lei H, Cai P, Zhu H, Li B,
Xu X, Xia Y and Tang W: Decreased miR-200a/141 suppress cell
migration and proliferation by targeting PTEN in Hirschsprung's
disease. Cell Physiol Biochem. 34:543–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
27
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and down-regulation of micro-RNA genes miR15 and
miR16 at 3q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:pp. 15524–15529. 2002, View Article : Google Scholar : PubMed/NCBI
|
28
|
Huang YH, Lin KH, Chen HC, Chang ML, Hsu
CW, Lai MW, Chen TC, Lee WC, Tseng YH and Yeh CT: Identification of
postoperative prognostic microRNA predictors in hepatocellular
carcinoma. PLoS One. 7:e371882012. View Article : Google Scholar : PubMed/NCBI
|
29
|
Cimmino A, Calin GA, Fabbri M, Lorio MV,
Ferracin M, Shimizu M, Wojcik SE, Ageilan RI, Zupo S, Dono M, et
al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:pp. 13944–13949. 2005, View Article : Google Scholar : PubMed/NCBI
|
30
|
Tsang WP and Kwok TT: Epigallocatechin
gallate up-regulation of miR-16 and induction of apoptosis in human
cancer cells. J Nutr Biochem. 21:140–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
31
|
Jiang Q, Zhang Y, Zhao M, Li Q, Chen R,
Long X, Fang W and Liu Z: miR-16 induction after CDK4 knockdown is
mediated by c-Myc suppression and inhibits cell growth as well as
sensitizes nasopharyngeal carcinoma cells to chemotherapy. Tumour
Biol. 37:2425–2433. 2016. View Article : Google Scholar : PubMed/NCBI
|
32
|
Pekarsky Y and Croce CM: Role of miR-15/16
in CLL. Cell Death Differ. 22:6–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
33
|
Cai CK, Zhao GY, Tian LY, Liu L, Yan K, Ma
YL, Ji ZW, Li XX, Han K, Gao J, et al: miR-15a and miR-16-1
downregulate CCND1 and induce apoptosis and cell cycle arrest in
osteosarcoma. Oncol Rep. 28:1764–1770. 2012. View Article : Google Scholar : PubMed/NCBI
|
34
|
Gordaliza M: Natural products as leads to
anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI
|
35
|
Ji HF, Li XJ and Zhang HY: Natural
products and drug discovery. Can thousands of years of ancient
medical knowledge lead us to new and powerful drug combination in
the fight against cancer and dementia? EMBO Rep. 10:194–200. 2009.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Chinese pharmacopoeia commission,
pharmacopoeia of the Peoples Repubic of Chian. Beijing: Chinese
medical science and technology press; pp. 2632010
|
37
|
Lin JM, Wei LH, Chen YQ, Liu XX, Hong ZF,
Sferra TJ and Peng J: Pien Tze Huang induced apoptosis in human
colon cancer HT-29 cells is associated with regulation of the Bcl-2
family and activation of caspase 3. Chin J Integr Med. 17:685–690.
2011. View Article : Google Scholar : PubMed/NCBI
|
38
|
Zhuang Q, Hong F, Shen A, Zheng L, Zeng J,
Lin W, Chen Y, Sferra TJ, Hong Z and Peng J: Pien Tze Huang
inhibits tumor cell proliferation and promotes apoptosis via
suppressing the STAT3 pathway in colorectal cancer mouse. Int J
Oncol. 40:1569–1574. 2012.PubMed/NCBI
|
39
|
Shen AL, Hong F, Liu LY, Lin JM, Zhuang
QC, Hong ZF and Peng J: Effects of Pien Tze Huang on angiogenesis
in vivo and in vitro. Chin J Integr Med. 18:431–436. 2012.
View Article : Google Scholar : PubMed/NCBI
|
40
|
Shen A, Hong F, Liu L, Lin J, Wei L, Cai
Q, Hong Z and Peng J: Pien Tze Huang inhibits the proliferation of
human colon carcinoma cells by arresting G1/S cell cycle
progression. Oncol Lett. 4:767–770. 2012.PubMed/NCBI
|
41
|
Shen A, Chen Y, Hong F, Lin J, Wei L, Hong
Z, Sferra TJ and Peng J: Pien Tze Huang suppresses IL-6-inducible
STAT3 activation in human colon carcinoma cells through induction
of SOCS3. Oncol Rep. 28:2125–2130. 2012. View Article : Google Scholar : PubMed/NCBI
|
42
|
Shen A, Lin J, Chen Y, Lin W, Liu L, Hong
Z, Sferra TJ and Peng J: Pien Tze Huang inhibits tumor angiogenesis
in a mouse model of colorectal cancer via suppression of multiple
cellular pathways. Oncol Rep. 30:1701–1706. 2013. View Article : Google Scholar : PubMed/NCBI
|
43
|
Chen H, Shen A, Zhang Y, Chen Y, Lin J,
Lin W, Sferra T and Peng J: Pien Tze Huang inhibits hypoxia-induced
epithelial-mesenchymal transition in human colon carcinoma cells
through suppression of the HIF-1 pathway. Exp Ther Med.
7:1237–1242. 2014. View Article : Google Scholar : PubMed/NCBI
|
44
|
Shen A, Chen H, Chen Y, Lin J, Lin W, Liu
L, Sferra TJ and Peng J: Pien Tze Huang overcomes multidrug
resistance and epithelial-mesenchymal transition in human
colorectal carcinoma cells via suppression of TGF-β pathway. Evid
Based Complement Alternat Med. 2014:6794362014. View Article : Google Scholar : PubMed/NCBI
|
45
|
Chen H, Feng J, Zhang Y, Shen A, Chen Y,
Lin J, Lin W, Sferra TJ and Peng J: Pien Tze Huang inhibits
hypoxia-induced angiogenesis via HIF-1a/VEGF-A pathway in
colorectal cancer. Evid-Based Complement Alternat Med.
2015:4542792015.PubMed/NCBI
|
46
|
Shen A, Lin W, Chen Y, Liu L, Chen H,
Zhuang Q, Lin J, Sferra TJ and Peng J: Pien Tze Huang inhibits
metastasis of human colorectal carcinoma cells via modulation of
TGF-β1/ZEB/miR-200 signaling network. Int J Oncol. 46:685–690.
2015. View Article : Google Scholar : PubMed/NCBI
|
47
|
Wei L, Chen P, Chen Y, Shen A, Chen H, Lin
W, Hong Z, Sferra TJ and Peng J: Pien Tze Huang suppresses the
stem-like side population in colorectal cancer cells. Mol Med Rep.
9:261–266. 2014. View Article : Google Scholar : PubMed/NCBI
|
48
|
Qi F, Wei L, Shen A, Chen Y, Lin J, Chu J,
Cai Q, Pan J and Peng J: Pien Tze Huang inhibits the proliferation,
and induces the apoptosis and differentiation of colorectal cancer
stem cells via suppression of the Notch1 pathway. Oncol Rep.
35:511–517. 2016. View Article : Google Scholar : PubMed/NCBI
|
49
|
Lin J, Feng J, Jin Y, Yan Z, Lai Z and
Peng J: Pien Tze Huang suppresses VEGF-C-mediated lymphangiogenesis
in colorectal cancer. Oncol Rep. 36:3568–3576. 2016. View Article : Google Scholar : PubMed/NCBI
|
50
|
Xu YY and Yu EX: Clinical analysis of the
analysis of the effect of Pien Tze Huang in treatment of 42
patients with moderate or advanced liver cancer. Shanghai J Tradit
Chin Med. 12:4–5. 1994.
|
51
|
Xu YY: The effect of Pien Tze Huang in
treatment of liver cancer is good. Med World. 11:622001.
|